INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Encompass Health Corporation - EHC
Werte in diesem Artikel
NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation ("Encompass" or the "Company") (NYSE: EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Encompass and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 15, 2025, citing federal data and inspection reports, The New York Times published an article alleging that for-profit hospitals run by Encompass perform below average on key safety measures. The article reported that "Encompass owns many of the rehabs with worse rates of potentially preventable, unplanned readmissions to general hospitals" including 34 facilities which "Medicare rated as having statistically significantly worse rates of potentially preventable readmissions." The article further described a number of "alarming mistakes" leading to fatalities of patients in the care of Encompass-owned facilities.
Following publication of the article, Encompass's stock price fell $12.39 per share, or 10.35%, to close at $107.28 per share on July 15, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-encompass-health-corporation---ehc-302512686.html
SOURCE Pomerantz LLP
Übrigens: Healthsouth und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Healthsouth
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Healthsouth
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Healthsouth Corp Registered Shs
Analysen zu Healthsouth Corp Registered Shs
Datum | Rating | Analyst | |
---|---|---|---|
27.06.2019 | Healthsouth Outperform | BMO Capital Markets | |
30.05.2019 | Healthsouth Overweight | Barclays Capital | |
14.12.2018 | Healthsouth Equal Weight | Barclays Capital | |
29.03.2018 | Healthsouth Buy | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
27.06.2019 | Healthsouth Outperform | BMO Capital Markets | |
30.05.2019 | Healthsouth Overweight | Barclays Capital | |
29.03.2018 | Healthsouth Buy | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Healthsouth Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Healthsouth Corp Registered Shs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen